Investor Presentation Full Year 2017

Investor Presentation Full year 2017 Slide 102 VictozaⓇ accounts for 21% of total sales in 2017 Reported currencies TresibaⓇ Sales full year 2017 (mDKK) Sales split Sales Q4 2017 (mDKK) Sales split 7,327 7% 1,880 7% LevemirⓇ 14,118 13% 3,346 12% NovoRapidⓇ 20,025 18% 4,568 16% NovoMix® 10,257 9% 2,457 9% VictozaⓇ 23,173 21% 6,305 23% SaxendaⓇ 2,562 2% 697 2% Diabetes care and Obesity¹ 92,877 83% 23,143 83% NovoSevenⓇ 9,206 8% 2,431 9% NorditropinⓇ 6,655 6% 1,709 6% Biopharmaceuticals¹ 18,819 17% 4,849 17% Total¹ 111,696 100% 27,992 100% 1 Values are higher than the sum of the total elements listed due to residual values from products not listed changing diabetes® novo nordisk

View entire presentation